SMMT
Summit Therapeutics Inc.·Healthcare
17.36
2.118%(+0.36)
Close PriceLast Updated: — ET
52W L: $13.8352W H: $30.98
SMMT NEWS
zacks.com
5d ago
Here's Why You Should Add SMMT Stock to Your Portfolio Now
Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.
prnewswire.com
May 18
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
zacks.com
May 18
Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
zacks.com
May 4
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
247wallst.com
May 4
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts.
globenewswire.com
May 4
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). The investigation focuses on Summit's executive officers and whether investor losses may be recovered under federal securities laws.
